ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
News, Short Squeeze, Breakout and More Instantly...
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND amended to include four additional TCRs, bringing the total number of evalua...
Shares of Ziopharm Oncology (NASDAQ: ZIOP) jumped by 10.8% on Wednesday. The clinical-stage biopharmaceutical company is examining non-viral T-cell receptor therapies (TCR-T) to fight cancer. Its shares closed on Tuesday at $0.8553, then opened Wednesday at $0.8770, climbing to a hi...
HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of preclinical data highlighting the potential of neoantigen-specific TCR-T cells for the treatment of solid tumors a...